Cassava Sciences Inc.
416 Browning Way
South San Francisco
278 articles about Cassava Sciences Inc.
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
Cassava Sciences Responds to Media Reports
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company.
Scientific Community Questions Anti-Amyloid Theory - the Basis for Seminal Alzheimer's Work
7/22/2022The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.
Cassava Sciences is reeling after another journal retracted an article co-authored by a key collaborator on its experimental Alzheimer's disease therapeutic, simufilam.
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
Cassava Sciences, Inc. announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022.
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer.
Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
Cassava Sciences, Inc. announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and presentation on Tuesday, April 5, 2022, at 9am Eastern time.
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
Shares of Cassava Sciences are up more than 5% in premarket trading after the FDA denied a Citizen Petition filed last year to suspend the company’s Alzheimer’s clinical trials.
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
Cassava Sciences, Inc., (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com. Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences’ Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimer’s disease.
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication
Cassava Sciences, Inc., a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators.
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Cassava Sciences, Inc., a biotechnology company, announced it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease.
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.